GB0011410D0 - Therapeutic combination for treating Alzheimer's disease - Google Patents

Therapeutic combination for treating Alzheimer's disease

Info

Publication number
GB0011410D0
GB0011410D0 GBGB0011410.8A GB0011410A GB0011410D0 GB 0011410 D0 GB0011410 D0 GB 0011410D0 GB 0011410 A GB0011410 A GB 0011410A GB 0011410 D0 GB0011410 D0 GB 0011410D0
Authority
GB
United Kingdom
Prior art keywords
disease
therapeutic combination
treating alzheimer
alzheimer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0011410.8A
Other versions
GB2352631A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Publication of GB0011410D0 publication Critical patent/GB0011410D0/en
Publication of GB2352631A publication Critical patent/GB2352631A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
GB0011410A 1999-05-20 2000-05-11 Inverse agonist of GABA-A alpha-5 receptor subtype & spheron disruption inhibitor combination for treating neurodegenerative conditions eg Alzheimer's disease Withdrawn GB2352631A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9911802.8A GB9911802D0 (en) 1999-05-20 1999-05-20 Therapeutic combination

Publications (2)

Publication Number Publication Date
GB0011410D0 true GB0011410D0 (en) 2000-06-28
GB2352631A GB2352631A (en) 2001-02-07

Family

ID=10853860

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9911802.8A Ceased GB9911802D0 (en) 1999-05-20 1999-05-20 Therapeutic combination
GB0011410A Withdrawn GB2352631A (en) 1999-05-20 2000-05-11 Inverse agonist of GABA-A alpha-5 receptor subtype & spheron disruption inhibitor combination for treating neurodegenerative conditions eg Alzheimer's disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB9911802.8A Ceased GB9911802D0 (en) 1999-05-20 1999-05-20 Therapeutic combination

Country Status (1)

Country Link
GB (2) GB9911802D0 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001945A (en) * 2000-09-06 2003-09-10 Neurogen Corp TETRAHYDROINDAZOLS REPLACED WITH ARILO AND ITS USE AS LIGANDOS FOR THE GABA-A RECEIVER.
JP2005535565A (en) * 2002-03-04 2005-11-24 ナイモックス コーポレーション Spheron components useful in determining compounds capable of treating Alzheimer's disease symptoms, and therapeutic and animal models produced from the components
US7514407B2 (en) 2002-03-04 2009-04-07 Nymox Corporation Spheron component peptides and pharmaceutical compositions
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
EP2682481A3 (en) * 2005-08-03 2014-09-17 The Johns-Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
MX346185B (en) 2010-11-15 2017-03-10 Agenebio Inc Pyridazine derivatives, compositions and methods for treating cognitive impairment.
NZ722077A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX2017015752A (en) 2015-06-19 2018-04-13 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment.
BR112019012821A2 (en) 2016-12-19 2019-11-26 Agenebio Inc benzodiazepine derivatives, compositions and methods for the treatment of cognitive impairment
JP2021528427A (en) 2018-06-19 2021-10-21 エージンバイオ， インコーポレイテッド Benzodiazepine derivatives, compositions and methods for treating cognitive impairment
CN114773352B (en) * 2022-06-20 2023-03-17 上海赛默罗生物科技有限公司 Process for preparing substituted nicotinamides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9503601D0 (en) * 1995-02-23 1995-04-12 Merck Sharp & Dohme Method of treatment and method of manufacture of medicament
US6465462B1 (en) * 1996-07-25 2002-10-15 Merck Sharp & Dohme Ltd. Substituted triazolo pyridazine derivatives as inverse agonists of the GABAAα5 receptor subtype
GB9622370D0 (en) * 1996-10-28 1997-01-08 Merck Sharp & Dohme Therapeutic agents
US6130221A (en) * 1997-03-05 2000-10-10 Nymox Corporation Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
JP4672820B2 (en) * 1997-05-08 2011-04-20 メルク シャープ エンド ドーム リミテッド Substituted 1,2,4-triazolo [3,4-a] phthalazine derivatives as GABAα5 ligands

Also Published As

Publication number Publication date
GB2352631A (en) 2001-02-07
GB9911802D0 (en) 1999-07-21

Similar Documents

Publication Publication Date Title
EP1043991A4 (en) Treatment for alzheimer's disease
AU2001233299A1 (en) Methods for treating alzheimer's disease
IL153214A0 (en) Compounds to treat alzheimer's disease
EP1007048A4 (en) Identification of agents for use in the treatment of alzheimer's disease
ZA989365B (en) Preparation for treating alzheimer's disease
AU6932000A (en) Tacrine derivatives for treating alzheimer's disease
HK1040184A1 (en) Combination therapy for treating glaucoma
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
GB0011410D0 (en) Therapeutic combination for treating Alzheimer's disease
GB0011408D0 (en) Therapeutic combination for treating Alzheimer's Disease
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
AU1405899A (en) Treatment for alzheimer's disease
GB0011430D0 (en) Acombination of therapeutic agents for treating Alzheimer's Disease
AU2266801A (en) Combination therapy for treating neurodegenerative disease
EP1181550A4 (en) Methods for the identification of compounds for the treatment of alzheimer's disease
IL142581A (en) Medicament for treating heart disease
IL120269A0 (en) 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
HRP20020778A2 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
AU5495398A (en) Idebenone containing combination agent for treating alzheimer's disease
GB0020261D0 (en) Therapeutic treatment
GB9709416D0 (en) Methods for treatment of alzheimer's disease using azaspiranes
AU2002340201A1 (en) Combination therapy for treating alzheimer's disease
GB9820489D0 (en) Compounds for improved treatment of parkinson's disease
GB2397018B (en) Combination therapy for treating disease

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)